10-K: INOVIO Pharmaceuticals Reports 2024 Results, Outlines Path to BLA Submission for INO-3107

INOVIO Pharmaceuticals details its 2024 financial results and provides an update on its clinical programs, including plans for a BLA submission for INO-3107 in mid-2025.

Summary

• INOVIO Pharmaceuticals, a clinical-stage biotechnology company, has released its 10-K filing for the fiscal year ended December 31, 2024.
• The company is focused on developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases.
• INOVIO's lead candidate is INO-3107 for recurrent respiratory papillomatosis (RRP), and the company plans to begin a rolling submission of the BLA in mid-2025 with a goal of file acceptance by the FDA by the end of 2025.
• INOVIO is also developing INO-3112 for oropharyngeal squamous cell carcinoma (OPSCC) in collaboration with Coherus BioSciences, with a planned Phase 3 clinical trial.
• Another key candidate is INO-5401 for glioblastoma multiforme (GBM), with ongoing consideration for further clinical investigation.
• The company incurred a net loss of $107.3 million in 2024, compared to a net loss of $135.1 million in 2023.
• Research and development expenses were $75.6 million in 2024, down from $86.7 million in 2023.
• As of December 31, 2024, INOVIO had cash and short-term investments of $94.1 million.
• The company anticipates its cash runway will extend through the fourth quarter of 2025.
• Management believes that there is substantial doubt about the company's ability to continue as a going concern beyond the fourth quarter of 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is progress on the clinical front with INO-3107 and collaborations, the financial situation and going concern warning raise concerns.

Positives

• The company is on track to begin a rolling submission of the BLA for INO-3107 in mid-2025.
• A manufacturing issue with the CELLECTRA 5PSP device, identified during testing, has been resolved.
• INOVIO has a clinical collaboration with Coherus BioSciences to evaluate INO-3112 in a Phase 3 trial for OPSCC.
• The company is considering options for further clinical investigation of INO-5401 in GBM.
• The net loss decreased to $107.3 million in 2024 from $135.1 million in 2023.
• Research and development expenses decreased to $75.6 million in 2024 from $86.7 million in 2023.

Negatives

• INOVIO incurred a net loss of $107.3 million in 2024.
• Management believes that there is substantial doubt about the company's ability to continue as a going concern beyond the fourth quarter of 2025.

Risks

• The company has incurred significant losses in recent years and expects to incur significant net losses in the foreseeable future.
• INOVIO will need substantial additional capital to develop its DNA medicines and proprietary device technology, which may prove difficult or costly to obtain.
• If INOVIO is unable to obtain FDA approval of its proprietary devices and DNA medicine candidates, it will not be able to commercialize them in the United States.
• Negative perception of the efficacy, safety, or tolerability of any investigational medicines or devices could adversely affect INOVIO's ability to conduct its business.
• The company faces intense and increasing competition, which may impede its ability to develop and commercialize its DNA medicines.
• Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect INOVIO's business.

Future Outlook

INOVIO anticipates its cash runway will extend through the fourth quarter of 2025 and plans to begin a rolling submission of the BLA for INO-3107 in mid-2025, targeting FDA file acceptance by the end of 2025.

Management Comments

• Management believes that there is substantial doubt about the company's ability to continue as a going concern beyond the fourth quarter of 2025.

Industry Context

The announcement reflects the ongoing challenges and high costs associated with drug development in the biotechnology industry, particularly for companies focused on novel therapeutic approaches like DNA medicines. Competition in the HPV and cancer therapy spaces is intense, requiring INOVIO to demonstrate clear clinical advantages and secure strategic partnerships.

Comparison to Industry Standards

• Comparing INOVIO's financial position to similar clinical-stage biotech companies, a cash runway through Q4 2025 is relatively short, necessitating further capital raises or partnerships.
• Companies like Precigen, also developing therapies for RRP, are key competitors, with Precigen having submitted a BLA for their product candidate.
• AstraZeneca and Bristol-Myers Squibb are major players in the head and neck cancer space, with established immunotherapies like nivolumab, setting a high bar for INOVIO's INO-3112.
• The success of Moderna and BioNTech with mRNA vaccines has validated nucleic acid-based therapies, but also increased scrutiny on safety and efficacy, impacting the perception of INOVIO's DNA medicines.

Legal Proceedings

• The company is involved in ongoing litigation with VGXI and GeneOne.
• The company has implemented corporate governance reforms in response to the provisions of the Stipulation of Settlement related to shareholder derivative litigation.

Related Party Transactions

• The company derived 100% and 29%, respectively, of its revenue from a single collaborator, ApolloBio, in 2024 and 2023.
• Dr. David B. Weiner, a director of the company, acts as a consultant to PLS.
• The company has collaborative research agreements with The Wistar Institute, where Dr. Weiner is a director of the Vaccine Center and an Executive Vice President.
• The company held 23% of the outstanding equity of Geneos Therapeutics, and Dr. Laurent Humeau, the company's Chief Scientific Officer, is on the Board of Directors of Geneos.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Patients could benefit from successful development and commercialization of INOVIO's DNA medicines.
• Suppliers and collaborators may be impacted by changes in the company's research and development priorities or financial constraints.

Next Steps

• Begin a rolling submission of the BLA for INO-3107 in mid-2025.
• Initiate a confirmatory clinical trial for INO-3107.
• Continue clinical collaboration with Coherus BioSciences to evaluate INO-3112 in a Phase 3 trial for OPSCC.
• Consider various options for continuing clinical investigation of INO-5401 in patients with GBM.
• Seek additional capital to fund future research and development activities.

Key Dates